Impact of Tecfidera on Gut Microbiota
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02736279|
Recruitment Status : Recruiting
First Posted : April 13, 2016
Last Update Posted : November 4, 2016
Objectives: Dimethyl fumarate (DMF) therapy may cause a measureable change in bacterial species of the gut. The primary objectives of this study are:
- Determine whether a measureable change in bacterial species representation follows the institution of DMF.
- Determine whether a specific pattern of change in the microbiota phylotype with DMF therapy correlates to onset and severity of gastrointestinal disturbances (heartburn, nausea, flatulence, and diarrhea).
- Determine whether any instability of microbiota phylotype representation persists following the institution of DMF or whether stabilization relates to resolution of gastrointestinal disturbances.
- Determine whether there is a correlation between a pre-existing functional bowel disorder and development or severity of gastrointestinal disturbances and of peripheral eosinophilia.
Design: Double-blinded, prospective, single-center pilot study.
Patient Population: Individuals 18 years or older, with a confirmed diagnosis of a relapsing form of multiple sclerosis.
Treatment Groups: This study will be an open-label prospective study design with respect to MS immunomodulatory therapy choice. Study group will be defined as subjects with a relapsing form of multiple sclerosis, as defined by the McDonald criteria, choosing to begin DMF therapy.
|Condition or disease||Intervention/treatment|
|Multiple Sclerosis||Drug: Dimethyl fumarate|
This will be an open-label prospective study design with respect to MS immunomodulatory therapy choice. Study group will be defined as subjects with a relapsing form of multiple sclerosis as defined by the McDonald criteria choosing to begin dimethyl fumarate (DMF) therapy. Blinding of the principal investigator and study subject to microbiota analysis results will be maintained until the planned end of study. Subjects who receive at least one dose of DMF and subsequently discontinue therapy will be invited to complete the study on alternative immunomodulatory therapy or no therapy. Data from subjects who have received at least one dose of DMF and who withdraw early from the study will be included in analysis as last visit carried forward. A goal has been set to enroll 25 subjects for this study.
Gut microbiota will be characterized using a commercial service, Second Genome, utilizing bacterial DNA extraction from stool samples and 16S ribosomal RNA gene amplification, followed by high-throughput sequencing. Taxonomic profiling on the Illumina MiSeq system is cycled to generate paired 250-bp reads in Second Genome's protocols. These longer read lengths provide high-quality full length-reads of the gene to ensure the most accurate classification available through sequencing technologies. Next generation sequencing has emerged as a powerful tool for investigating microbial communities in large sample sets.
Serial stool samples will be collected from each subject, and sent to Second Genome for analysis. The first stool sample will be collected prior to the initial dose of DMF, with subsequent collections at defined time points over the course of the study. A more intensive analysis will focus on the first 12 weeks of treatment, a time during which development and resolution of gastrointestinal side effects typically take place on therapy. Treatment-emergent flushing severity will be recorded during this time using a 5-point Likert scale flushing severity survey. Gastrointestinal (G.I.) symptoms will be assessed using the Gastrointestinal Symptoms Rating Scale (GSRS) questionnaire, a validated, self-administered questionnaire that includes 15 questions, which assess severity of G.I. symptoms using a 7-point Likert scale in five domains: indigestion, diarrhea, constipation, abdominal pain and reflux. The severity of symptoms reported in the GSRS increases with increasing score. Other variables which potentially may alter the gastrointestinal microbiota and secondarily DMF tolerance will be assessed, including the identification of subjects predisposed to functional bowel disorders via use of the Rome III functional bowel survey, a validated clinical tool to identify at-risk individuals, diet composition, antibiotic exposure, steroid treatments for neurological relapses, use of prebiotic , probiotic, or vitamin D supplements, and H2 blocker or proton pump inhibitor (PPI) therapy, as gut pH changes impact the gut flora composition.Additional data on mood change over 24 weeks of DMF therapy, using the Hamilton Anxiety Measurement (HAM) Rating Scale and Patient Health Questionnaire-9 (PHQ-9) Depression Scale, will be collected and correlated to DMF-emergent G.I. disturbances, and to changes in bacterial and archaeal species in the gut flora.
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Official Title:||Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate With Gastrointestinal Disturbances Following Therapy Initiation?|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||December 2020|
- Drug: Dimethyl fumarate
Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapyOther Name: Tecfidera
- Measure change in the diversity and relative abundance of bacterial and archaeal species in the gut microbiota following the start of DMF therapy. [ Time Frame: Weeks 0 (baseline), 4,8,12,and 24 ]16S ribosomal RNA gene sequencing for taxanomic classification of both known and unknown bacteria. This method quantifies the relative abundance of bacterial and archaeal species at each time point of sampling, and changes in the composition of species at specified time points from baseline (weeks 0, 4, 8, 12, and 24 following DMF treatment initiation.
- Measure change in anxiety level within the first 6 months following the start of dimethyl fumarate therapy. [ Time Frame: Weeks 0 (baseline), 12, and 24 ]Prospective analyses of anxiety severity comparing the aggregate score from the Hamilton Anxiety Measurement (HAM) at baseline visit prior to the start of DMF therapy to the aggregate score obtained at weeks 0 (baseline prior to therapy), 12 and 24.
- Measure change in depression level within the first 6 months following the start of dimethyl fumarate therapy. [ Time Frame: Weeks 0 (baseline), 12, and 24 ]Prospective analyses of depression severity comparing the aggregate score from the Patient Health Questionnaire-9 (PHQ-9) Depression Scale survey at baseline visit (week 0) prior to the start of DMF therapy to the aggregate score obtained at weeks 12 and 24 from start of therapy.
- Define pre-existing functional bowel disturbance as a predictor of GI symptoms development and severity following the start of dimethyl fumarate treatment. [ Time Frame: Weeks 0 (baseline); 1-12 and 24 ]Baseline functional GI disturbances will be quantified by the Rome III functional bowel survey prior to initiating dimethyl fumarate therapy (week 0). Following treatment initiation, developing gastrointestinal symptoms and their severity will be measured by the Gastrointestinal Symptoms Rating Scale at selected time points (weekly for the first 12 weeks, and at week 24) within the first 6 months of DMF treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02736279
|Contact: Shalom E Kilcup||425-899-5369||SEKilcup@evergreenhealth.com|
|Contact: Carey L Gonzales||425-899-5374||CLGonzales@evergreenhealth.com|
|United States, Washington|
|EvergreenHealth MS Center||Recruiting|
|Kirkland, Washington, United States, 98034|
|Contact: Shalom E Kilcup 425-899-5369 SEKilcup@evergreenhealth.com|
|Principal Investigator: Virginia I Simnad, MD, M.Sc|
|Sub-Investigator: Theodore R Brown, MD, MPH|
|Principal Investigator:||Virginia I Simnad, MD||EvergreenHealth|